Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“Pfizer has initiated a global Phase 3 clinical trial for our novel targeted therapy in adults with HR+, HER2- advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatments.
While treatment options have evolved, resistance and disease progression continue to pose serious challenges for people living with MBC. This potential first-in-class therapy is a selective inhibitor of epigenetic modifiers KAT6A and KAT6B and was discovered and developed by Pfizer scientists in collaboration with researchers in Australia.
It has shown encouraging early clinical activity when combined with endocrine therapy, and if successfully developed and approved, we believe this therapy may help address a significant unmet need for people with HR+, HER2- MBC.
A heartfelt thank you to our principal investigators, research teams, and especially the patients participating in this trial. Your contributions are vital to advancing science and transforming care.
Learn more about our commitment to transforming breast cancer care.”
Proceed to the video attached to the post.
More posts featuring Chris Boshoff.